Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials.
Lehtinen M, Gray P, Luostarinen T, Eriksson T, Apter D, Bly A, Harjula K, Heikkilä K, Hokkanen M, Kuortti M, Nieminen P, Nummela M, Paavonen J, Palmroth J, Petäjä T, Pimenoff VN, Pukkala E, Dillner J.
Lehtinen M, et al. Among authors: eriksson t.
Front Cell Infect Microbiol. 2024 Sep 9;14:1437704. doi: 10.3389/fcimb.2024.1437704. eCollection 2024.
Front Cell Infect Microbiol. 2024.
PMID: 39315334
Free PMC article.
Clinical Trial.